The biopharmaceutical industry must continuously evolve to keep up with changing trends.
The authors present an overview of the types of RNA-based therapeutics in existence and their optimal methods of manufacture, purification, formulation, and delivery.
The authors present an overview of the types of RNA-based therapeutics in existence and their optimal methods of manufacture, purification, formulation, and delivery.
The authors present an overview of the types of RNA-based therapeutics in existence and their optimal methods of manufacture, purification, formulation, and delivery.
The authors present an overview of the types of RNA-based therapeutics in existence and their optimal methods of manufacture, purification, formulation, and delivery.
The authors present an overview of the types of RNA-based therapeutics in existence and their optimal methods of manufacture, purification, formulation, and delivery.
The authors present an overview of the types of RNA-based therapeutics in existence and their optimal methods of manufacture, purification, formulation, and delivery.
The author outlines key functional attributes to assess a small-scale model.
A streamlined approach may enhance process efficiency and product quality.
New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.
The authors outline cell-line development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality.
The authors outline cell-line development and process scale-up for an antibody program in which the antibody requires additional processing by a site-specific enzyme for correct functionality.
The authors describe the qualification of an assay with applications for investigating functional comparability of an originator and biosimilar drug.
FDA’s focus on the quality culture and its request for quality metrics may ensure a successful company-CMO relationship.
A structured assessment process can determine compliance to lifecycle process-validation requirements for biopharmaceuticals.
Quality, flexibility, and cost savings are driving use of perfusion technology in biosimilars manufacturing.
Quality, flexibility, and cost savings are driving use of perfusion technology in biosimilars manufacturing.
Pharmaceutical companies need to radically change to survive and thrive amid shifting healthcare and technology changes.
A technology management process identifies and evaluates new technologies in biopharmaceutical manufacturing to aid business decisions.
A technology management process identifies and evaluates new technologies in biopharmaceutical manufacturing to aid business decisions.
A technology management process identifies and evaluates new technologies in biopharmaceutical manufacturing to aid business decisions.
A technology management process identifies and evaluates new technologies in biopharmaceutical manufacturing to aid business decisions.
A technology management process identifies and evaluates new technologies in biopharmaceutical manufacturing to aid business decisions.
An approach to stabilize PBS-based formulations could provide a simple physiological solution for use of proteins in research, preclinical, diagnostics, and clinical studies, as well as commercial biotherapeutic products.
An approach to stabilize PBS-based formulations could provide a simple physiological solution for use of proteins in research, preclinical, diagnostics, and clinical studies, as well as commercial biotherapeutic products.
An approach to stabilize PBS-based formulations could provide a simple physiological solution for use of proteins in research, preclinical, diagnostics, and clinical studies, as well as commercial biotherapeutic products.
The authors present a case study in which four single-use vessels were fitted to an existing bioreactor system.